Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus salmeterol/fluticasone for COPD exacerbation prevention
NL-OMON41239Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QVA149 with Seretide (2 arms). Primary endpoint: COPD exacerbation rate. Started Jul 2013; status: active, not recruiting.
02
Drugs
indacaterol + glycopyrroniumsalmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON41239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41239.